Showing 1 - 4 of 4 Items
Showing 1 - 4 of 4 Items
Sort By: Relevance
Journal Article
|Research
2025-02-01 • Lancet Global Health
2025-02-01 • Lancet Global Health
BACKGROUND
New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...
Journal Article
|Research
2022-12-07 • PLOS Global Public Health
2022-12-07 • PLOS Global Public Health
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PR...
Journal Article
|Pre-Print
2022-11-10 • medRxiv
2022-11-10 • medRxiv
INTRODUCTION
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent eviden...
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent eviden...
Protocol
|Research Protocol
2020-10-10 • BMJ Open
2020-10-10 • BMJ Open
INTRODUCTION
Current treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the costs of treating MDR-TB are...
Current treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the costs of treating MDR-TB are...